These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
203 related items for PubMed ID: 32392105
21. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility. Singh BN. J Cardiovasc Electrophysiol; 1999 Feb; 10(2):283-301. PubMed ID: 10090235 [Abstract] [Full Text] [Related]
22. [Anti-arrhythmia agents]. Kaufmann G. Med Klin; 1974 May 03; 69(18):778-86. PubMed ID: 4134645 [No Abstract] [Full Text] [Related]
23. [Anti-arrhythmia treatment (clinical problems, classification of anti-arrhythmia drugs and personal experience]. Walczak F. Kardiol Pol; 1992 May 03; 36(2):97-104. PubMed ID: 1583833 [No Abstract] [Full Text] [Related]
24. Modernized Classification of Cardiac Antiarrhythmic Drugs. Lei M, Wu L, Terrar DA, Huang CL. Circulation; 2018 Oct 23; 138(17):1879-1896. PubMed ID: 30354657 [Abstract] [Full Text] [Related]
25. New perspectives in the pharmacologic therapy of cardiac arrhythmias. Singh BN, Collett JT, Chew CY. Prog Cardiovasc Dis; 1980 Oct 23; 22(4):243-301. PubMed ID: 6986060 [No Abstract] [Full Text] [Related]
26. Postrepolarization refractoriness in acute ischemia and after antiarrhythmic drug administration: action potential duration is not always an index of the refractory period. Coronel R, Janse MJ, Opthof T, Wilde AA, Taggart P. Heart Rhythm; 2012 Jun 23; 9(6):977-82. PubMed ID: 22293142 [Abstract] [Full Text] [Related]
28. Is there a need for new antiarrhythmic drugs? Roden DM. Arch Mal Coeur Vaiss; 1996 Feb 23; 89 Spec No 1():13-8. PubMed ID: 8734158 [Abstract] [Full Text] [Related]
30. German Cardiac Society Working Group on Cellular Electrophysiology state-of-the-art paper: impact of molecular mechanisms on clinical arrhythmia management. Thomas D, Christ T, Fabritz L, Goette A, Hammwöhner M, Heijman J, Kockskämper J, Linz D, Odening KE, Schweizer PA, Wakili R, Voigt N. Clin Res Cardiol; 2019 Jun 23; 108(6):577-599. PubMed ID: 30306295 [Abstract] [Full Text] [Related]
31. [Effect of various drugs on A-V conduction by means of study of the His bundle]. Mobilij A, D'Annunzio E, di Matteo L. Boll Soc Ital Cardiol; 1977 Jun 23; 22(12):2332-41. PubMed ID: 755510 [No Abstract] [Full Text] [Related]
32. Postrepolarization refractoriness: a mechanism in need for a molecule? Kirchhof P, Fabritz L. Heart Rhythm; 2012 Jun 23; 9(6):983-4. PubMed ID: 22334152 [No Abstract] [Full Text] [Related]
33. After a long time, the new ESC Guidelines for the management of patients with supraventricular tachycardia are here. Tamargo J. Eur Heart J Cardiovasc Pharmacother; 2020 Jan 01; 6(1):3-5. PubMed ID: 31800023 [No Abstract] [Full Text] [Related]
35. MY APPROACH to early repolarization syndrome. Yan GX. Trends Cardiovasc Med; 2016 May 01; 26(4):393-4. PubMed ID: 26944231 [No Abstract] [Full Text] [Related]
36. [Diagnosis and treatment of arrhythmia in ambulatory practice]. Pomerantsev VP. Sov Med; 1990 May 01; (8):36-40. PubMed ID: 2274818 [No Abstract] [Full Text] [Related]
37. Class III antiarrhythmic drugs. Singh BN, Ahmed R. Curr Opin Cardiol; 1994 Jan 01; 9(1):12-22. PubMed ID: 8199363 [Abstract] [Full Text] [Related]
38. Arrhythmias and antiarrhythmic drugs. Bigger JT. Adv Intern Med; 1972 Jan 01; 18():251-81. PubMed ID: 4576083 [No Abstract] [Full Text] [Related]
39. Novel K+ Channel Targets in Atrial Fibrillation Drug Development--Where Are We? El-Haou S, Ford JW, Milnes JT. J Cardiovasc Pharmacol; 2015 Nov 01; 66(5):412-31. PubMed ID: 25978691 [Abstract] [Full Text] [Related]